Related Experiment Video
Updated: May 5, 2026
06:58
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
6.3K
[Memory and cognitive impairment of the elderly]
1Department of Psychiatry, Osaka University Graduate School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 23, 2013
Summary
Memory loss in older adults, including subjective cognitive impairment and mild cognitive impairment, is a pathological sign, not normal aging. Research into these conditions may help prevent dementia.
Area of Science:
- Gerontology
- Neuroscience
- Pathology
Context:
- Subjective cognitive impairment and mild cognitive impairment represent preclinical stages of dementia in the elderly.
- Historically viewed as physiological brain aging, memory impairment is now recognized as a pathological phenotype.
- These conditions offer a critical window for research into dementia prevention.
Purpose:
- To reframe the understanding of memory impairment in the elderly from physiological aging to a pathological condition.
- To highlight the potential of targeting subjective cognitive impairment and mild cognitive impairment for dementia prevention strategies.
- To explore the relevance of brain reserve and cognitive reserve hypotheses in mitigating elderly memory decline.
Summary:
- Memory impairment in the elderly, encompassing subjective cognitive impairment and mild cognitive impairment, is a pathological brain phenotype, not a normal aspect of aging.
- This understanding shifts the focus towards these conditions as key targets for interventions aimed at preventing dementia.
- The study discusses brain and cognitive reserve hypotheses as potential frameworks for overcoming memory decline.
Impact:
- Provides a revised pathological perspective on elderly memory impairment, crucial for dementia research.
- Establishes subjective cognitive impairment and mild cognitive impairment as vital targets for developing dementia prevention therapies.
- Introduces brain and cognitive reserve hypotheses as promising avenues for future research and clinical application in combating cognitive decline.
Related Concept Videos
01:30Cognitive Development During Adulthood
1.4K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K
01:15Drug Dosing: Geriatric Patients
400
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
400
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
932
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
932
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
376
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
376